LCG
ADMA icon

Lisanti Capital Growth’s ADMA Biologics ADMA Stock Holding History

Lisanti Capital Growth’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-83,555
Closed -$1.52M – 104
2025
Q4 		$1.52M Buy
83,555
+3,933
+5% +$66.3K 0.36% 92
2025
Q3 		$1.17M Sell
79,622
-196,333
-71% -$3.37M 0.29% 89
2025
Q2 		$5.03M Sell
275,955
-32,485
-11% -$662K 1.39% 26
2025
Q1 		$6.12M Buy
308,440
+132,970
+76% +$2.3M 1.82% 9
2024
Q4 		$3.01M Sell
175,470
-59,565
-25% -$1.12M 0.72% 65
2024
Q3 		$4.7M Buy
+235,035
New +$3.65M 1.19% 31

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Lisanti Capital Growth's ADMA Position: Q1 2026 in Review

Lisanti Capital Growth sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 83,555 shares — an estimated $1.52M sold.

Lisanti Capital Growth first reported a position in ADMA in Q3 2024 and held it in 6 quarters. The position peaked at $6.12M in Q1 2025. 357 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Lisanti Capital Growth reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Lisanti Capital Growth sold 83,555 ADMA Biologics shares in Q1 2026, an estimated $1.52M.
  • Lisanti Capital Growth first reported a position in ADMA Biologics in Q3 2024 and held it in 6 quarters.
  • Lisanti Capital Growth's ADMA Biologics position peaked at $6.12M in Q1 2025.
  • 357 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Lisanti Capital Growth's 13F filing for Q1 2026, filed 7 May 2026.